Teva Contests 2 Of Gilead’s Truvada Patents

Law360, New York (November 17, 2008, 12:00 AM EST) -- Israel-based Teva Pharmaceutical Industries Inc. is taking steps to gain regulatory approval to market a generic version of Gilead Sciences Inc.’s lucrative HIV medication Truvada and has challenged two of the 10 patents covering the drug as invalid and unenforceable, according to Gilead.

Gilead said Friday it received a letter that Teva submitted an abbreviated new drug application to the U.S. Food and Drug Administration to make and market a Truvada generic, and said it has 45 days to decide whether to launch a patent infringement...
To view the full article, register now.